NxGen MDx Announces National Contract with Aetna
GRAND RAPIDS, Mich., Feb. 9, 2017 /PRNewswire/ -- NxGen MDx, a company that provides innovative genetic testing solutions, announced today that its genetic screening and non-invasive pre-natal testing will be available on an in-network basis for Aetna health plans' 40+ million members beginning on February 15, 2017.
Aetna, the third largest health plan in the United States, included NxGen's products following a thorough review of their products' unique features, such as full-gene sequencing, and the additional incremental benefits they will provide to the physician network that focuses on women's healthcare. Many physicians supported the inclusion of NxGen MDx in the network due to their stated belief that NxGen MDx's suite of services are best-in-class tools and aid in informed decision-making. According to Dr. Mark Perloe, Medical Director at Georgia Reproductive Specialists in Atlanta, "having NxGen MDx in the Aetna network allows me the flexibility to use the testing services that I believe are in my patients' best interest."
"Like NxGen MDx, Aetna's goal is to provide tools to help physicians and patients make informed decisions about their health care. We are both trying to accomplish the same goal," says Alan Mack, CEO of NxGen MDx.
Aetna will cover all of NxGen's testing at a national level, providing its 46 million members with in-network access to best-in-class and comprehensive genetic testing in the marketplace. NxGen MDx offers testing for up to 120 various genetic disorders through panels and stand-alone screens
"Patients will now have in-network access to best-in-class genetic testing. This removes a barrier for many health care professionals who have wanted to use our testing in the past," says Kristin Sherman, CFO of NxGen MDx.
About NxGen MDxNxGen MDx LLC is a leading women's health company delivering highly accurate and precise genetic screening to detect genetic diseases or abnormalities to help guide family planning decisions for couples and their health care providers. Unlike other laboratories, NxGen MDx's technology examines the entire gene rather than parts of the gene, giving families a comprehensive assessment of their true risk. NxGen MDx is located in Grand Rapids, Michigan. To learn more, visit the company's website at www.nxgenmdx.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nxgen-mdx-announces-national-contract-with-aetna-300405115.html
SOURCE NxGen MDx